There are 2185 resources available
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
Resources:
Abstract
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
Resources:
Abstract
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15
Resources:
Abstract
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
Resources:
Abstract
542P - Long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trial
Presenter: Huabin Hu
Session: Poster session 15
Resources:
Abstract
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18
Resources:
Abstract
543P - Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
Presenter: Anne Ree
Session: Poster session 15
Resources:
Abstract
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
Resources:
Abstract
544P - Nivolumab plus ipilimumab in microsatellite instability high (MSI)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study
Presenter: Léonard Depotte
Session: Poster session 15
Resources:
Abstract
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
Resources:
Abstract